ERBB2 and non-small cell lung carcinoma: Recently, Trastuzumab Deruxtecan (T-DXd) has demonstrated superior survival outcomes and received accelerated approval by the FDA for treating patients with NSCLC carrying HER2 (ERBB2) mutations on August 11, 2022.